GSK (LON:GSK) Share Price Passes Above 200-Day Moving Average – What’s Next?

GSK plc (LON:GSK)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,980.11 and traded as high as GBX 1,990.50. GSK shares last traded at GBX 1,979.50, with a volume of 4,305,542 shares traded.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Shore Capital Group reissued a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Citigroup cut their target price on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a report on Thursday, May 28th. Berenberg Bank reiterated a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a research report on Thursday, March 26th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 1,900 price objective on shares of GSK in a research note on Monday, June 8th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of GBX 2,034.29.

GSK Price Performance

The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73. The firm has a market capitalization of £78.57 billion, a PE ratio of 13.80, a P/E/G ratio of 1.24 and a beta of 0.30. The company has a 50-day moving average price of GBX 1,923.51 and a 200-day moving average price of GBX 1,981.10.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, April 29th. The company reported GBX 46.50 EPS for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%.The firm had revenue of GBX 762.90 billion during the quarter. Sell-side analysts forecast that GSK plc will post 175.980975 EPS for the current year.

Insider Activity

In other news, insider Wendy Becker acquired 4,000 shares of the business’s stock in a transaction dated Wednesday, April 29th. The stock was acquired at an average price of GBX 1,963 per share, with a total value of £78,520. Also, insider Vishal Sikka acquired 1,266 shares of GSK stock in a transaction that occurred on Monday, June 22nd. The shares were purchased at an average cost of GBX 5,069 per share, for a total transaction of £64,173.54. In the last ninety days, insiders have acquired 7,630 shares of company stock valued at $21,357,859. 0.20% of the stock is owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.